Crescent Biopharma Inc - Company Profile
Powered by 
All the sales intelligence you need on Crescent Biopharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Crescent Biopharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Crescent Biopharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Crescent Biopharma Inc (Crescent Biopharma), formerly GlycoMimetics Inc, is a clinical-stage biotechnology company focused on developing transformative therapies for cancer treatment. The company leverages its expertise in carbohydrate chemistry to create small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in various disease states. Crescent Biopharma is involved in the research, development, and commercialization of therapies for blood cancers and hematologic diseases, serving the healthcare and pharmaceutical industries.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Crescent Biopharma is actively engaged in research and development initiatives focused on advancing its pipeline of oncology therapeutics. The company's R&D efforts are centered around two main strategies: the development of CR-001, a PD-1 x VEGF bispecific antibody, and the creation of a robust portfolio of antibody-drug conjugates (ADCs). CR-001 is designed to bind both the PD-1 immune checkpoint and Vascular Endothelial Growth Factor (VEGF), potentially replacing pembrolizumab (Keytruda) as the foundational immuno-oncology backbone. The company initiated the ASCEND trial, a global Phase 1/2 trial of CR-001, in February 2026, targeting up to eight solid tumor types. Additionally, Crescent Biopharma is building a portfolio of potentially best-in-class ADCs, designed to work synergistically with CR-001 to transform cancer care. The company plans to initiate clinical trials for CR-002 and CR-003 (SKB105) in 2026. Strategic partnerships and collaborations with academic institutions and cancer centers further support the advancement of its drug candidates. In FY2025, the company spent US$138.1 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer